Sep. 21, 2016 - September 20, 2016, NEW YORK — A Ludwig Cancer Research study published online September 14th in Nature reports a novel technique to map specific chemical (or “epigenetic”) modifications made to the protein packaging of DNA using a small population of cells. Such epigenetic marks play a central role in the regulation of the genome’s expression. Led jointly by Ludwig San Diego’s Bing Ren and Arne Klungland of the University of Oslo, the authors describe their application of this method to unravel a key mystery of the earliest stage of development. The new technique, named μChIP-seq, is also likely to be of notable relevance to cancer research.
Very soon after fertilization, the control of embryonic development shifts from pre-existing maternal gene products to the products of genes encoded by the early embryo (or zygote). This passing of the genetic baton, called the maternal-to-zygotic transition (MZT), is poorly understood because existing technologies have generally been too insensitive to capture the full scale of the epigenetic changes it entails across the zygotic genome.
The improved sensitivity of μChIP-seq, developed jointly by Klugland, Ren and John Arne Dahl of Oslo University, led to “some remarkable discoveries that have completely changed our view of epigenetic inheritance mechanisms,” says Ren.
In the current paper, Ren and his colleagues describe their use of μChIP-seq to investigate how epigenetic information is passed from one generation to the next to orchestrate the MZT. To that end, they examined in mouse embryos the global distribution of an epigenetic mark known to play a critical role in regulating the activity of genes. This mark (H3K4me3) modifies chromatin—the complex of DNA and its protein packaging—by adding three identical molecules known as methyl groups at a specific place on a packaging protein known as histone 3.
Dahl, a visiting scholar in Ren’s lab and co-first author on the Nature paper, fine-tuned the technique for mapping such epigenetic tags to where only a few hundred embryos or cells were needed for each experiment. Previous methods required up to 10,000 cells to conduct similar analyses. The other first author, Inkyung Jung, a Ludwig postdoc in Ren’s lab, contributed significantly to the computational analysis of the resulting data.
When the scientists compared H3K4me3 distribution in immature mouse egg cells they found something unexpected: broad but distinct domains of the immature egg cell’s genome, representing some 22% of the whole, are heavily marked by H3K4me3. These domains rapidly decrease in size in 2-cell embryos and eventually shrink to about 1% to 2% of the genome.
“The key lesson we learned was that the genes that are destined to be turned on specifically in the fertilized egg are covered by this unique chromatin domain structure,” says Ren. Those marks have to be removed by specialized enzymes to activate the zygotic genome. “This mark is a mechanism for the oocyte to influence which genes in the zygote are activated. It is an epigenetic mechanism for the passage of information from the maternal oocyte to the zygote.”
The ability to map “epigenomes” using such a small number of cells will be valuable to cancer research, since the epigenetic landscape is dramatically rearranged in cancer and contributes to phenomena driven by small subpopulations of cells, such as drug resistance and metastasis.
“With a better understanding of the epigenetic landscapes in cancers, we are going to have more tools to study the basis of tumorigenesis,” says Ren. “We still have a long way to go, but our goal is to have a thorough understanding of gene regulatory programs so we can use that knowledge to treat cancer and develop diagnostic tools.”
This research was funded by Ludwig Cancer Research, the American Heart Association, the Oslo University Hospital Early Career Award, the Norwegian Cancer Society, the Anders Jahre Foundation and the Norwegian Research Council.
# # #
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested nearly $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
For further information please contact Rachel Steinhardt, firstname.lastname@example.org or +1-212-450-1582.
Tell us what you think of Chemistry 2011 -- we welcome both positive and negative comments. Have any problems using the site? Questions?